MK2 inhibitor reduces alkali burn-induced inflammation in rat cornea
Yanfeng Chen1, Wenzhao Yang1, Xiaobo Zhang1
1Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Xiamen, Fujian, China.
Abstract:
MK2 activation by p38 MAPK selectively induces inflammation in various diseases. We determined if a MK2 inhibitor (MK2i), improves cornea wound healing by inhibiting inflammation caused by burning rat corneas with alkali. Our study, for the first time, demonstrated that MK2i inhibited alkali burn-induced MK2 activation as well as rises in inflammation based on: a) blunting rises in inflammatory index, inflammatory cell infiltration, ED1(+) macrophage and PMN(+) neutrophil infiltration; b) suppressing IL-6 and IL-1β gene expression along with those of macrophage inflammatory protein-1α (MIP-1α), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1); c) reducing angiogenic gene expression levels and neovascularization (NV) whereas anti-angiogenic PEDF levels increased. In addition, this study found that MK2i did not affect human corneal epithelial cell (HCEC) proliferation and migration and had no detectable side effects on ocular surface integrity. Taken together, MK2i selectively inhibited alkali burn-induced corneal inflammation by blocking MK2 activation, these effects have clinical relevance in the treatment of inflammation related ocular surface diseases.
Insights
A novel MK2 inhibitor (MK2i) effectively reduces inflammation and promotes cornea wound healing after alkali burns. This targeted approach improves ocular surface integrity without impacting cell proliferation or migration.
Area of Science:
- Ophthalmology
- Inflammation Research
- Molecular Biology
Background:
- p38 MAPK-activated MK2 plays a key role in inflammation.
- Alkali burns cause significant corneal inflammation and impair wound healing.
- Targeting MK2 activation may offer a therapeutic strategy for ocular surface diseases.
Purpose of the Study:
- To investigate the efficacy of a MK2 inhibitor (MK2i) in improving cornea wound healing following alkali burns.
- To determine if MK2i can inhibit inflammation by blocking MK2 activation in alkali-burned rat corneas.
Main Methods:
- Induction of alkali burns in rat corneas.
- Administration of a MK2 inhibitor (MK2i).
- Assessment of inflammatory markers, cell infiltration, gene expression (IL-6, IL-1β, MIP-1α, ICAM-1, VCAM-1), angiogenic factors, and ocular surface integrity.
Main Results:
- MK2i significantly inhibited alkali burn-induced MK2 activation and reduced the inflammatory index.
- MK2i decreased inflammatory cell infiltration (macrophages, neutrophils) and suppressed key inflammatory and adhesion molecule gene expression.
- MK2i reduced neovascularization and promoted an increase in anti-angiogenic PEDF, without affecting corneal epithelial cell proliferation or migration.
Conclusions:
- MK2i selectively inhibits alkali burn-induced corneal inflammation by blocking MK2 activation.
- MK2i demonstrates potential as a therapeutic agent for inflammation-related ocular surface diseases.
- The study highlights the clinical relevance of targeting MK2 for treating inflammatory corneal conditions.
